ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 7, 2021

8:30AM-10:30AM: Abstract Number: 0584

High Number of Comorbidities and Concomitant Medications at Baseline in the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) Study: An Older Population with Rheumatoid Arthritis

Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

8:30AM-10:30AM: Abstract Number: 0715

High-Dimensional Analysis Reveals Abnormal B Cell Subsets Associated with Specific Changes to Circulating T and Myeloid Cell Populations in Patients with Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0628

Higher Quality of Care for Patients with Systemic Lupus Erythematosus in a Subspecialty Lupus Clinic: A Multi-Setting Cross-Sectional Study

Measures & Measurement of Healthcare Quality Poster (0623–0659)

8:30AM-10:30AM: Abstract Number: 0909

How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Ankylosing Spondylitis? – Real World Data from a German Observational Study

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

8:30AM-10:30AM: Abstract Number: 0606

How Might We Care for Rheumatoid Arthritis (RA) Patients Unable to See a Rheumatologist And/or Use Certain of Our Medications? Proposed Preliminary Recommendations for RA Patients Who Don’t Meet Our Established Guidelines

Healthcare Disparities in Rheumatology Poster (0594–0622)

8:30AM-10:30AM: Abstract Number: PP07

How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic

Patient Perspectives Poster (PP01–PP09)

8:30AM-10:30AM: Abstract Number: 0578

Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years

Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

8:30AM-10:30AM: Abstract Number: 0533

Identification of a Novel Susceptibility Locus for Small Vessel Vasculitis with Autoantibodies Against Myeloperoxidase

Genetics, Genomics & Proteomics Poster (0517–0533)

8:30AM-10:30AM: Abstract Number: 0856

Identifying COVID-19 Infection Rates and Outcomes in Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Manifestations (0855–0896)

8:30AM-10:30AM: Abstract Number: 0553

IgG from Systemic Sclerosis Patients Induce a Profibrosing and Serotype-dependent Phenotype in Normal Dermal Fibroblast: A Multi-omics Study

Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

8:30AM-10:30AM: Abstract Number: 0712

Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0835

Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice

RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

8:30AM-10:30AM: Abstract Number: 0692

Immunophenotyping of Inclusion Body Myositis Blood T Cells: Pathogenic and Biomarker Implications

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0690

Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis

Muscle Biology, Myositis & Myopathies Poster (0683–0722)

8:30AM-10:30AM: Abstract Number: 0925

Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs

Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis (0908–0939)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].